Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Medicine 105

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 145

Law Legalization Clinical Trials CBD 145

Cannabis Law Report

SEPTEMBER 10, 2021

They have a strong pedigree in drug development which fits perfectly with the commercial and clinical expertise we have built within the Clerkenwell Health team”. Octarine Bio is a synthetic biology company based in Copenhagen, Denmark, which aims to deliver innovative cannabinoid and psychedelic treatments to improve health and wellbeing.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. The study examines the effect of the cannabinoid Cannabidivarin, more commonly referred to as CBDV , on irritability and repetitive behaviors in children with autism spectrum disorder.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

MMJ Recs

JULY 9, 2024

In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients. ” Other cannabinoids, like cannabinol (CBN) and cannabigerol (CBG), also contribute to the plant’s medicinal benefits.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Veriheal

JUNE 29, 2021

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

JUNE 17, 2021

As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 83

Pharmaceutical Clinical Trials Therapy Programs 83

CannaMD

NOVEMBER 15, 2020

research scene is also dominated by research on the harmful effects of cannabis, but Canada has dedicated much more funding to positive cannabinoid research. As such, universities such as McMaster University and McGill University , among others, have built dedicated and comprehensive research programs. Furthermore, since 2014, the U.S.

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

Veriheal

APRIL 11, 2022

He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based. federal law, from which point, informed choices can be made about the use of cannabis and cannabinoids. territories.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Veriheal

JULY 7, 2023

Plants hit with HLVd show issues like yellow leaves, abnormal branching, stunted development, and nearly 50% loss in cannabinoid production. Canada, and Israel are all conducting clinical trials on psychedelic treatments. Further, the bill would establish an advisory board and commission to oversee the program.

Legalization 97

Legalization Clinical Trials Research and Development History 97

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

CannaMD

NOVEMBER 8, 2019

The VA, through VHA Directive 1315 , confirms: Veterans must not be denied VA services solely because they are participating in state-approved marijuana programs. According to the VA : Veteran participation in state marijuana programs does not affect eligibility for VA care and services. PTSD Studies Support Cannabis.

Marijuana 85

Marijuana Treatment Research and Development Patients 85

LifeCannMD

MAY 27, 2025

Ways to save money: First-time patient discounts at dispensaries Compassionate care programs for low-income families Loyalty programs and regular sales Payment plans for larger purchases Why Legal Matters More Than You Think Look, I get it. .” When the FDA Finally Caught Up You know what really legitimized all this for me?

CBD 52

CBD Oil Epilepsy Sleep 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

CannaMD

AUGUST 8, 2020

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system.

CBD 105

CBD DEA Research and Development Hemp 105

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 12, 2021

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

MedicalJane

JUNE 29, 2018

Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. percent of tetrahydrocannabinol (THC), the cannabinoid responsible for producing “high” psychoactive effects when consumed. Clinical trials show that Epidiolex significantly reduces seizure frequency. Prior to this week, the U.S.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

The Cannigma

JULY 1, 2022

However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application. Moreover much of the research done has focused on synthetic pharmaceutical grade cannabinoids developed by pharmaceutical companies.

Research and Development 124

Research and Development Data THC Clinical Trials 124

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo.

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

Cannabis Law Report

NOVEMBER 22, 2021

Emyria was listed on the ASX last year, just before Australia was plunged into the global COVID-19 pandemic, and has been progressing with trials of a synthetic cannabinoid targeting mental health which it hopes to have registered domestically and in the American market.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

MAY 10, 2022

The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. The findings were published today in Frontiers in Pharmacology.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Puff Puff Post

SEPTEMBER 16, 2019

Santé Cannabis, a pioneer in medical cannabis in Québéc , has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

Programs 40

Programs Research and Development Education Treatment 40

Medicinal Marijuana Association

AUGUST 27, 2019

Based on such revelations, programs such as the one established byIsraeli Ministry of Health are able to provide eligible patients with the necessary permits to legally purchase medical cannabis. More clinical trials in cannabis are currently being conducted in this tiny countrythan in any other country across the globe.

Research and Development 66

Research and Development Clinical Trials Patients Epilepsy 66

Puff Puff Post

JANUARY 13, 2020

Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. So even when patients use CBD oil with essentially no THC, doctors need to understand a lot more about the complex chemical reactions of cannabinoids and terpenes. Preliminary Research on CBD Oil. Physicians at Mt.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. So even when patients use CBD oil with essentially no THC, doctors need to understand a lot more about the complex chemical reactions of cannabinoids and terpenes. Preliminary Research on CBD Oil. Physicians at Mt.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. In this position, Mr. Anderson will be responsible for Anebulo’s global investor relations and public relations programs.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 5, 2021

The review excludes pre-clinical trials (i.e. Professor Mark Connor is a molecular pharmacologist with expertise in analgesics and psychoactive drugs, particularly cannabinoids and opioids, with extensive research experience in the USA, UK, and Australia. experimental pharmacology studies in test tube or animal models).

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Freedom Leaf

JANUARY 10, 2018

“We’re actively working toward developing new genetics to work on efficacy and assist the patients in Israel still operating with our nurse-run clinics in order to better provide the right dosage and strains for the patients who are referred to us by the Ministry of Health,” Stephen Gardner, Tikun Olam’s chief marketing officer, tells Freedom Leaf.

Research and Development 49

Research and Development Clinical Trials Strains Patients 49